comparemela.com
Home
Live Updates
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies : comparemela.com
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Palazestrant in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...
Related Keywords
Hollywood ,
California ,
United States ,
Massachusetts ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Texas ,
San Francisco ,
San Antonio ,
Nedlands ,
Western Australia ,
Australia ,
Marlene Chan ,
Seanp Bohen ,
Geoffrey Mogilner ,
Henryb Gonzalez Convention Center ,
Company Investor Webcast ,
Breast Cancer Research ,
Curtin University ,
Nasdaq ,
Exchange Commission ,
Olema Pharmaceuticals Inc ,
Securities Exchange ,
Poster Spotlight Session ,
San Antonio Breast Cancer Symposium ,
Convention Center ,
Antonio Breast Cancer Symposium ,
Chief Executive Officer ,
Breast Clinical Trials Unit ,
Hollywood Private Hospital ,
Investor Webcast ,
Securities Act ,
Securities Exchange Act ,
Quarterly Report ,
Vice President ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.